Jim Cramer: This Health Care Stock Is A ‘Winner’, X-Energy Is ‘Losing Too Much Money’

Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

Wall Street Analysts Update McKesson Price Targets

Multiple major financial institutions have updated their ratings and price targets for McKesson Corporation, with targets now ranging between $1,200 and $1,260.

McKesson and Clayton, Dubilier & Rice Secure $3.1 Billion Financing for Option Care Health Acquisition

McKesson Corporation and private equity firm Clayton, Dubilier & Rice have engaged Wall Street banks to arrange $3.1 billion in financing to support their acquisition of Option Care Health.

Orchestra BioMed Announces Pricing of Public Offering

Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 15 million shares at $5.00 per share, expected to raise $75 million in gross proceeds. The company plans to use the funds to advance its AVIM Therapy program and BACKBEAT clinical trial for hypertension treatment, as well as its Virtue SAB program for coronary in-stent restenosis, alongside other research and development initiatives.

UBS Maintains Buy on McKesson, Raises Price Target to $1250

Medtronic and Recor Medical Report Real-World Evidence for Renal Denervation

Medtronic and Recor Medical have released new real-world evidence demonstrating the clinical performance of their renal denervation technology.